October 2, 2023

ALEXANDRIA, Va. –– The American Society of Clinical Oncology (ASCO) has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials. The statement, published today in Lancet Oncology, emphasizes the urgent need to understand the long-term impacts of cancer therapies on ovarian function. 

September 5, 2023

The American Society of Clinical Oncology (ASCO) will join the President’s Cancer Panel on Sept. 7 to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve the president’s Cancer Moonshot goal of “ending cancer as we know it.”

July 18, 2023

ALEXANDRIA, Va. -- The American Society of Clinical Oncology (ASCO) has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this disease: dose optimization and individualization. Despite breast cancer being more prevalent in people age 65 or older, few from this age group, particularly those above 75, are included in CDK4/6 inhibitor clinical trials. 

May 15, 2023

Today President Biden announced the nomination of current National Cancer Institute Director (NCI), Dr. Monica Bertagnolli, to become Director of the National Institutes of Health (NIH).

May 1, 2023

ALEXANDRIA, Va. – More than 150 members of the Association of Clinical Oncology (ASCO), the leading professional organization for oncology professionals, will meet with Members of Congress on Tuesday urging them to make cancer care a top priority.

“Lawmakers have a profound effect on cancer patients and their doctors. From funding the research that leads to new groundbreaking treatments, to ensuring those treatments are covered by insurance and accessible and affordable to patients; lawmakers play a pivotal role,” said ASCO Board Chair Lori J. Pierce, MD, FASTRO, FASCO.

April 19, 2023

Today members of the U.S. House of Representatives unveiled a proposed legislative deal to reduce federal spending in exchange for raising the nation’s debt ceiling. The proposal includes significant funding cuts to federal agencies, which would include resources for the National Institutes of Health (NIH) and National Cancer Institute (NCI). It also proposes adding work requirements for Medicaid enrollment.

A statement from Dr. Julie Gralow, Chief Medical Officer and Executive Vice President, Association of Clinical Oncology follows:

April 3, 2023

ALEXANDRIA, Va.—Today the National Cancer Institute (NCI) released an ambitious National Cancer Plan designed to accelerate scientific progress against the disease, maximize the potential of discovery and achieve the goal of the Cancer Moonshot initiative to “end cancer as we know it.”

March 30, 2023

ALEXANDRIA, Va. – “Today’s ruling is a significant step backward in the effort to reduce cancer incidence and death. By reversing the now more than decade-long requirement that insurance plans cover proven cancer screenings—including those for breast, colon, and lung—health plans could reinstate cost-sharing and patients could once again be forced to weigh the potentially lifesaving benefit of a doctor-recommended cancer screening against the out-of-pocket costs it may generate.

March 15, 2023

ALEXANDRIA, Va. – In a study of more than 1,100 people with COVID-19 undergoing treatment for cancer, researchers found lower COVID-19 vaccination rates among patients with comorbidities, metastatic solid tumors or non-B-cell hematologic malignancies, and those living in areas with lower education attainment and higher levels of unemployment. The study, funded by Conquer Cancer®, the ASCO Foundation, was published today in Cancer. 


February 8, 2023

“ASCO applauds President Biden’s focus on ‘ending cancer as we know it’ during the State of the Union address. We continue to urge the president to keep cancer care and research as top national priorities and are pleased with his plans to advance efforts to strengthen the Cancer Moonshot, improve cancer clinical trials, and foster breakthroughs through the Advanced Research Projects Agency for Health (ARPA-H).”


February 7, 2023

In anticipation of President Biden’s State of the Union Address, the Association for Clinical Oncology (ASCO) is urging the president to keep cancer care and research as top national priorities. 

February 2, 2023

Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.

January 11, 2023

Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published today in JCO Oncology Practice.

October 26, 2022

The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) today released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The statement was published in the AACR’s journal Clinical Cancer Research and ASCO’s Journal of Clinical Oncology.

October 17, 2022

In conjunction with the World Cancer Congress, the American Society of Clinical Oncology, Inc. (ASCO®) is publishing a special series of its online publication JCO Global Oncology focused on innovative, evidence-based models for cancer professionals and patients to improve access to quality cancer care particularly in low- and middle-income countries (LMICs).